Serum microRNA-196 and microRNA-200 in pancreatic ductal adenocarcinoma of patients with diabetes mellitus.
OBJECTIVE
Our aim was to compare expressions of 6 microRNAs (miRNAs) in patients with pancreatic ductal adenocarcinoma (PAC) and non-cancer patients, moreover according to the presence or absence of diabetes mellitus.


METHODS
Expressions of miRNA-192, -196, -200, -21, -30 and -423 were measured in 77 patients with PAC and 64 non-cancer patients (34 patients with type 2 DM and 30 control persons). 60 patients with PAC (78%) had DM or prediabetes and it was of new-onset (less than 2 years before the cancer diagnosis) in 44 out of them.


RESULTS
The expressions of all microRNAs were 1.4-3.7 times higher (significantly) in the PAC group compared to non-cancer patients. No difference was found between PAC diabetic and PAC non-diabetic patients. MicroRNA-200 was significantly higher in PAC patients with significant body weight loss against those without weight loss. Adding miRNA-196 and -200 to the current marker CA 19-9 improved the discriminative ability of the test (compared to CA 19-9 alone).


CONCLUSIONS
MicroRNA-196 and -200 could be used as additional markers in PAC diagnosis.
2nd Department of Internal Medicine, 3rd Faculty of Medicine, Charles University, Faculty Hospital Královské Vinohrady, Prague, Czech Republic. Electronic address: pavel.skrha@email.cz.
Pavel
P
Škrha
3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University, General Faculty Hospital, Prague, Czech Republic.
Aleš
A
Hořínek
Institute of Biology and Medical Genetics, 1st Faculty of Medicine, Charles University, General Faculty Hospital, Prague, Czech Republic.
Eva
E
Pazourková
2nd Department of Internal Medicine, 3rd Faculty of Medicine, Charles University, Faculty Hospital Královské Vinohrady, Prague, Czech Republic.
Jan
J
Hajer
Department of Internal Medicine, 1st Faculty of Medicine, Charles University, Military University Hospital, Prague, Czech Republic.
Přemysl
P
Frič
3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University, General Faculty Hospital, Prague, Czech Republic.
Jan
J
Škrha
2nd Department of Internal Medicine, 3rd Faculty of Medicine, Charles University, Faculty Hospital Královské Vinohrady, Prague, Czech Republic.
Michal
M
Anděl
D000368:Aged; D000369:Aged, 80 and over; D001786:Blood Glucose / Q000032:analysis; D018395:CA-19-9 Antigen / Q000032:analysis; D021441:Carcinoma, Pancreatic Ductal / Q000150:complications / Q000235:genetics* / Q000378:metabolism; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000235:genetics* / Q000378:metabolism; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000096:biosynthesis / Q000235:genetics*; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000150:complications / Q000235:genetics* / Q000378:metabolism; D011236:Prediabetic State / Q000235:genetics / Q000378:metabolism; D015431:Weight Loss
D001786:Blood Glucose; D018395:CA-19-9 Antigen; D006442:Glycated Hemoglobin; D035683:MicroRNAs; C542543:MIRN196 microRNA, human; C533896:MIRN200 microRNA, human
Biomarker; CA 19-9; Pancreatic cancer; miRNA